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Abstract
Background:Tobacco smoking affects both the fraction of exhaled nitric oxide (FeNO) and blood
eosinophil (B-Eos) count, two clinically useful biomarkers in respiratory disease that represent local
and systemic type-2 inflammation, respectively.Objective:Weaimed to study the influence of
objectivelymeasured smoke exposure on FeNOandB-Eos in a large population of subjects with and
without asthma.Methods:Weutilized theUSNationalHealth andNutrition Examination Surveys
2007–2012 and included 10 669 subjects aged 6–80 years: 9869 controls and 800 asthmatics. Controls
were defined as having no respiratory disease, no hay fever in the past year, and B-Eos count0.3×
109 l−1. Asthmawas defined as self-reported current asthma and at least one episode of wheezing or an
asthma attack in the past year, but no emphysema or chronic bronchitis. Tobacco usewas collected via
questionnaires and serum cotininewasmeasuredwithmass spectrometry.Results: Increasing cotinine
levels were associatedwith a progressive reduction in FeNO in both controls and asthmatics. FeNO
remained significantly higher in asthmatics than controls except in the highest cotinine decile,
equivalent to an average reported consumption of 13 cigarettes/day. B-Eos count increasedwith
cotinine in controls, but was unchanging in asthmatics. Interestingly, B-Eos countwas significantly
higher in presently non-exposed (cotinine below detection limit) former smokers than never smokers.
Conclusion: Smoke exposure decreases FeNOand increases B-Eos count. These effects should be
considered in the development of normalized values and their interpretation in clinical practice. The
persistence of elevated B-Eos in former smokers warrants further studies.
Introduction
Asthma is a chronic disease, characterized by inflamma-
tion of the airways, and defined by respiratory symp-
toms, such as wheeze and shortness of breath, along
with variable expiratory airflow limitation [1]. Various
phenotypes are described, such as atopic asthma with
eosinophilia, non-atopic eosinophilic asthma, and type-
2-low asthma [2]. These manifestations of the disease
can be evaluated using biomarkers such as the fraction
of exhaled nitric oxide (FeNO) and blood eosinophil
(B-Eos) count [3]. FeNO is recognized as a marker of
airway inflammation that is primarily triggered by IL-4
and IL-13 [4], and is increasinglyused in clinical practice
[5]. Elevated B-Eos is a marker of systemic eosinophilic
inflammation, common in asthma [6], and is primarily
triggered by IL-5 [4]. It has been shown that it might be
advantageous to assess both these pathways of inflam-
mation, as both local and systemic type-2 inflammation,
independent of each other, are important for the
development of respiratory symptoms and clinical
asthma [3, 7].
However, FeNO and B-Eos count are both affected
by endogenous and exogenous factors [8, 9], For exam-
ple, both current and past smoking were associated with
reduced airway and alveolar levels of NO [10]. In con-
trast, smokerswere shown to have increased numbers of
eosinophils in induced sputumsamples [11].
One of the limitations of determining smoking
habits and exposure to tobacco smoke is the use of
self-reported measures, which seem to have a poor
correlation with objective markers such as cotinine, a
metabolite of nicotine [12]. Further, cotinine mea-
surement seems to be especially useful to correctly
determine the amount of passive smoking [13]. Coti-
nine measurement in blood seems to have better per-
formance thanmeasurements in urine or saliva [14].
Thus, there is evidence of inflammatory changes
caused by smoking in asthmatics, changes that could
lead to a decreased response to corticosteroids and
increased susceptibility to infection [15]. Moreover,
increased serum cotinine was found to be associated
with an increased number of asthma exacerbations and
healthcare usage innon-smokerswith asthma [16].
In this study, we aim to investigate the influence of
active and passive exposure to cigarette smoke, objec-
tively determined using serum cotinine, on FeNO and
B-Eos count, in (a) healthy children and adults with no
history of respiratory diseases, and (b) individuals with
self-reported asthma, who have been included in the
National Health and Nutrition Examination Surveys
2007–2012.
Methods
Participants
The participants of this study were selected from the
publicly available datasets of the National Health and
Nutrition Examination Survey (NHANES), which is a
nationally representative series of studies designed to
assess the health and nutritional status of adults and
children in the United States, combining interviews
and physical examinations conducted by the National
Centre for Health Statistics, a part of the Centre for
Disease Control and Prevention. More detailed infor-
mation is available online at: www.cdc.gov/nchs/
nhanes/about_nhanes.htm.
From a total of 30 442 participants in NHANES
2007–2012, we have included individuals that per-
formed a FeNO measurement (n = 19800; 65%). Of
these, we have excluded 4583 individuals who ate NO-
rich vegetables in the 3 h before FeNO measurement,
or had a cough, cold, or respiratory illness in the seven
days before testing, and one individual with a FeNO
value of >300 ppb. Furthermore, we have excluded
participants without a valid cotinine (n = 1171) or
B-Eos (n = 46) measurement. A detailed flowchart
with the inclusion and exclusion criteria is shown in
figure 1.
Figure 1. Inclusion and exclusion criteria flowchart.
Two groups were created, (1) controls (n = 9869)
and (2) asthma (n = 800). Healthy individuals were
defined as having no previous diagnosis of asthma,
emphysema, or chronic bronchitis, and no hay fever in
the past 12 months. Participants with B-Eos 0.4 or
reporting hay fever in the past 12 months or currently
taking inhaled medication were excluded (n = 2786),
as were those reporting having COPD (n = 240).
Asthma was defined as self-reported physician-
diagnosed asthma at any time of life together with a
positive answer to the following question: ‘Do you still
have asthma?’ and at least one episode of wheezing or
an asthma attack in the past 12months.
ExhaledNO
FeNOwasmeasured before spirometrywas performed
with an electrochemical analyser (NIOXMINO; Aero-
crine AB, Solna, Sweden) in subjects aged6 years. A
valid measurement was defined in accordance with
ATS/ERS guidelines [17] as: having two reproducible
measurements at an expiratory flow rate of 50 ml s−1,
no use of oral or inhaled steroids in the past two days,
no breathing problems requiring oxygen, no problems
taking deep breaths, no strenuous exercise in the hour
prior to themeasurement, in addition to the exclusion
criteria described above. Up to four FeNO measure-
ment attempts were made and the mean of two
reproducible FeNO measurements (within 2 ppb if
levels were <30 ppb or within 10% if levels were
>30 ppb) was taken as the final result. The lower and
upper detection limits of NIOX MINO are 5 and
300 ppb, respectively. If two measurements were
below the limit of detection of the device (5 ppb), a
value of 3.5 ppb (lower limit of detection divided by
the square root of two)was used as themean.
Blood eosinophils
Blood was collected from participants by a phleboto-
mist. Complete blood count was analysed using the
Coulter method. The white blood cell differential uses
VCS technology. Analysis and classification of WBCs
use three simultaneous measurements of individual
cell volume (V ), high frequency conductivity (C), and
laser light scatter (S). The parameters analysed were
the absolute and relative number of eosinophils.
Further details are available (https://n.cdc.gov/
Nchs/Nhanes/2011-2012/CBC_G.htm).
Smoking habits
Included individuals were categorized into three
groups: current smokers, former smokers, and never
smokers. Current smokers were defined as subjects
who reported smoking at least 100 cigarettes in their
lifetime and who, at the time of survey, smoked either
every day or some days. Former smokers were defined
as subjects who reported smoking at least 100 cigar-
ettes in their lifetime and who, at the time of the
survey, did not smoke at all. Never smokers were
defined as individuals who reported having smoked
less than 100 cigarettes in their lifetime. An additional
category was created, non-smokers, by adding the
former smokers to the never smokers, representing
the individuals that did not currently smoke, regard-
less of past smoking habits. Since the questions
regarding smoking habits were only posed to adults,
the included individuals were divided into two groups:
children (age<18 years) and adults (age18 years).
Cotinine
Cotinine is a major metabolite of nicotine that can be
used as amarker for active smoking and as an index for
environmental tobacco smoke exposure. Cotinine is
generally preferred over nicotine for such assessments
because of its substantially longer half-life [18, 19].
Cotinine was measured in the participant’s serum,
using an isotope-dilution high-performance liquid
chromatography/atmospheric pressure chemical
ionization tandem mass spectrometric (ID HPLC-
APCI MS/MS) method. The detection limit was
0.015 ng ml−1. If the participant had a cotinine value
below the detection limit, the detection limit divided
by the square root of two was used. Further details are
available (https://n.cdc.gov/Nchs/Nhanes/2011-
2012/COTNAL_G.htm).
The number of individuals consuming other
forms of tobacco or under nicotine replacement ther-
apy was very low in both the control group (chewing
tobacco—n = 106, 1.1%; snuff—n = 44, 0.4%; pat-
ches, gums, others—n = 24, 0.2%) and the asthma
group (chewing tobacco—n= 3, 0.4%; snuff—n= 1,
0.1%; patches, gums, other—n = 2, 0.2%), and did
not have a significant impact on the results (data not
shown). There was no information available on the
usage of e-cigarettes, although we believe that this
usage would be minimal during the survey years
2007–2012.
Ethics
All protocols were approved by the Ethics Review
Board of the National Centre for Health Statistics
Research. All participants provided written informed
consent.
Statistical analysis
The skewness of the distribution of continuous
variables was assessed with the Kolmogorov–Smirnov
test and visual assessment of the histograms. The
reference group was composed of participants with
cotinine levels equal to or less than the detection limit
of 0.015 ng ml−1 (n = 2610, 24.5%). The remaining
groups were created using percentiles 10, 50 and 90 in
all participants (controls and asthmatics together)with
a cotinine value greater than the lower limit of
detection; these percentiles were chosen to better
accommodate the skewed distribution of cotinine and
to allow incremental average numbers of cigarettes
smoked per day (geometric mean) in the different
strata of serum cotinine as shown in table 1.
To obtain normal distributions, FeNO and B-Eos
were natural log-transformed before the analysis, and
described using geometric means and 95% confidence
intervals. Both these variables were corrected for age and
gender, when applicable [20]. Associations were tested
with one-way and two-way ANOVA tests, when applic-
able, with ln(FeNO) and ln(B-Eos) as the dependent
variable, which was back-transformed for interpreta-
tion. Relative differences in the geometricmeanbetween
the reference stratum and the other strata were calcu-
lated using the formula: (Stratum—Reference Group)/
Reference Group * 100. All the statistical analyses were
performed using IBM SPSS Statistics 24 (Chicago, IL,
USA) and Graphpad Prism v 6·05 (La Jolla, CA, USA).
The significance levelwas set toα=0.05.
Results
We have included 10 669 subjects (54% of total
NHANES participants aged six years and up during
the survey years 2007–2012) with valid FeNO, B-Eos,
and cotinine measurements: 9869 (92.5%) healthy
controls and 800 (7.5%) participants with asthma
(figure 1). Participant characteristics are shown in
table 2.
There were slightly more females in the asthma
group than in the control group, and the controls had
a higher mean age than the asthma group. No sig-
nificant effect of medication on FeNO and B-Eos
count in the different cotinine strata was found. There
were more smokers in the asthma group, and more
never smokers in the control group, whereas the pro-
portion of former smokers was similar among asth-
matics and controls. In addition, a proportion of 7.6%
of former smokers and 7.5% of never smokers pre-
sented with high levels of cotinine when analysing
controls and asthmatics together (figure E1 is available
online at stacks.iop.org/JBR/11/036006/mmedia).
The asthma group had higher B-Eos count, FeNO and
cotinine levels (0.301 versus 0.207 ng ml−1, p< 0.001)
compared with the control group. The proportions of
the different cotinine groups were mostly equally dis-
tributed, with the exception of the reference stratum,
with a higher proportion in the control group, and the
second highest stratum, with a higher proportion in
the asthma group.
Increasing cotinine levels were associated with
lower levels of FeNO (figure 2(A)). There were sig-
nificant differences compared with the reference stra-
tum for the two highest cotinine strata, corresponding
to an average of 6.5 or 12.7 cigarettes smoked per day,
respectively. Moreover, in the highest cotinine stra-
tum, the difference in FeNO between controls and
asthmatics had disappeared (table 3). The relative dif-
ferences were gradual, with a decrease of 42% in the
control group and 64% in the asthma group in the
Table 1.Comparison of the average number of cigarettes smoked in
the past 30 days between different cotinine strata.
Cotinine strata n
Average number of cigarettes
smoked in the past 30 days
Percentiles 10, 50
and 90
0.016–0.021 655 1.6
0.022–0.164 2388 2.3
0.165–283.0 2376 6.5
>283.0 539 12.7
Percentiles 25, 50
and 75
0.016–0.034 1519 2.5
0.035–0.164 1524 2.1
0.165–86.7 1519 3.3
>86.7 1426 10.3
Table 2.Description of included individuals.
Controls
n= 9869
Asthma
n= 800 p
Gender
Malen (%) 5012 (51) 374 (47) 0.028
Female n (%) 4857 (49) 426 (53)
Age (years) 35.8 (20.5) 29.7 (19.6) <0.001
Age (<18 years) n (%) 2507 (25) 306 (38) <0.001
Age (18 years) n (%) 7362 (75) 494 (62)
Smoking status n (%)
Current smoker 1385 (20.0) 125 (27.7) <0.001
Former smoker 1534 (22.2) 106 (23.5) NS
Never smoker 3996 (57.8) 221 (48.9) <0.001
Medication use n (%)#
Inhaled or oral
corticosteroids
NA 168 (21)
Leukotriene
modifiers
NA 80 (10)
Cotinine n (%)
0.015 2453 (25) 157 (20) 0.001
0.016–0.021 867 (9) 62 (8)
0.022–0.122 2935 (30) 235 (29)
0.123–239.6 2903 (29) 282 (35)
>239.6 711 (7) 62 (8)
BMI (kg m−2) 26.5 (7.0) 27.2 (8.5) 0.009
Blood eosinophils
(1000 cells μl−1)
127 (0.7) 212 (8.2) <0.001
FENO (ppb) 11.9 (0.1) 15.9 (0.9) <0.001
All categorical variables are represented by n (%). Age and body
mass index (BMI) are represented by mean (SD). The remaining
variables are represented by geometric mean (SEM). NS: not
significant. NA: not available.#: Participants were asked to refrain
from takingmedication at least 2 days before FeNOmeasurement.
highest cotinine stratum. The absolute difference was
larger in asthmatics than controls for most cotinine
strata, at least in adults (table E1).
The cotinine strata, corresponding to the percen-
tiles 10, 50 and 90 of each age group, differed between
children and adults, which should be recognized when
interpreting the results.
A contrasting effect of tobacco smoke exposure
was seen for the B-Eos count, as shown in figure 2(B).
There was no clear effect of increasing cotinine levels
in asthmatics, but there was a significant effect in con-
trols, with increasing B-Eos counts in the two highest
cotinine strata. The difference between controls and
asthmatics remained significant for B-Eos in all coti-
nine strata (table 4). The direction of the effect of
increasing cotinine levels on the B-Eos count was
different in controls and asthmatics, with fewer con-
trols than asthmatics showing a reduction in B-Eos
comparedwith the reference stratum (table E1).
The effect of increasing cotinine on FeNO and
B-Eos was consistent when dividing the participants
by gender (tables E2 and E3). In addition, there was no
significant effect of recent smoking, as defined in the
question.
A similar effect of tobacco smoke exposure on
FeNO and B-Eos was also seen in non-smoking con-
trols (never smokers plus former smokers), whereas
passive smoke exposure did not seem to affect FeNO
in asthmatics (figure 3).
When looking specifically at participants with
cotinine levels<0.015 ng ml−1, there was a significant
difference in FeNO between never smokers and
Figure 2.Relative differences of FeNO andB-Eos between cotinine strata and the reference stratum, in controls and asthma. FeNO
andB-Eos are represented by geometricmean and 95% confidence intervals (filled squares and circle withwhiskers, respectively).#:
Significant difference from the reference cotinine stratum (0.015) at p< 0.001 (corrected for age). Note that the cotinine strata are
not the same in the different groups; categories: (a) all subjects: 1 ‘0.015’, 2 ‘0.016–0.021’, 3 ‘0.022–0.122’, 4 ‘0.123–239.6’, 5
‘>239.6’, (b) age<18 years 1 ‘0.015’, 2 ‘0.016–0.020’, 3 ‘0.021–0.078’, 4 ‘0.079–2.315’, 5 ‘>2.315’, (c) age>18 years 1 ‘0.015’, 2
‘0.016–0.021’, 3 ‘0.022–0.164’, 4 ‘0.165–283.0’, 5 ‘>283.0’.
former smokers in controls and asthmatics (p= 0.001
and p < 0.001, respectively), but was not consistent
after adjusting for age and gender (p = 0.47 and
p= 0.31, respectively). However, never smoking con-
trols had significantly lower B-Eos count than former
smokers, even after adjusting for age and gender (p <
0.001) (figure 4).
Furthermore, there was no significant effect of
recent cigarette smoking on FeNO, defined as smok-
ing in the hour prior to FeNO measurement, in self-
reported smokers, regardless of asthma diagnosis and
gender, after adjustment for age and serum cotinine
(table E4).
Discussion
This study is the first to report the effect of objectively
measured exposure to cigarette smoke both on exhaled
NO and blood eosinophils. The effects were compared in
healthy controls and asthmatics, with children and adults
analysed separately. Increasing serumcotinine levelswere
associated with lower FeNO, starting at cotinine levels
corresponding to approximately six cigarettes per day in
active smokers; this effect appeared to be slightly larger in
asthmatics than controls. However, FeNO remained
higher in asthmatics than controls for all cotinine strata
except the highest decile, corresponding to an average
consumption of 13 cigarettes per day. The effect of
increasing cotinine levels on B-Eos count was different,
with a significant increase in controls and non-significant
variations in asthmatics. Interestingly, past active cigarette
smoking seemed to be related to persistent type-2
inflammation, as indicated by increased B-Eos count in
presently non-exposed former smokers compared with
never smokers.
Cigarette smoking has long been known to reduce
FeNO in healthy subjects [21]. This effect was recently
studied using the NHANES dataset, but with children
and adults grouped together [22]. However, cigarette
smoke exposure differs greatly between children and
adults (present data) and normal FeNO is lower in
children than adults [20], which strongly suggests that
children and adults should be analysed separately.
Further, Xu et al [22] did not report the effect on FeNO
in terms of absolute values and did not relate cotinine
levels to cigarette smoke consumption, which makes
our study more useful for clinicians. Exhaled NO is
also reduced in smokers with asthma, but FeNO
may still be used to differentiate asthmatic from non-
asthmatic subjects [23]. The relative effect of smoking
on FeNO in subjects with asthma versus controls has
not been examined previously in a large population.
Further, the effect of smoke exposure on FeNO and
Table 3.Effect of increasing serum cotinine on FeNO in the control and asthma groups.
Controls Asthma
Cot. (ng ml−1) * n FeNO n FeNO p
All individuals
 0.015 2453 13.2 (12.9–13.5) 157 19.8 (17.5–22.4) <0.001
0.016–0.021 867 13.2 (12.6–13.8) 62 19.4 (15.5–24.2) <0.001
0.022–0.122 2935 13 (12.7–13.3) 235 17.7 (15.9–19.8) <0.001
0.123–239.6 2903 10.9 (10.6–11.1) 282 14.8 (13.3–16.5) <0.001
>239.6 711 7.6 (7.3–7.9) 64 7.4 (6.2–8.7) 0.726
Age<18 years
 0.015 677 10.3 (9.8–10.8) 65 18.4 (14.7–23) <0.001
0.016–0.020 206 10.3 (9.4–11.2) 15 20.4 (10.6–39.4) <0.001
0.021–0.078 740 10.1 (9.7–10.6) 90 17.7 (14.3–21.8) <0.001
0.079–2.315 701 9.8 (9.4–10.3) 115 14.7 (12.3–17.5) <0.001
>2.315 183 9.2 (8.4–10.1) 21 14.1 (8.6–23.2) 0.009
Age18 years
0.015 1776 14.5 (14.1–14.8) 92 20.8 (18–24) <0.001
0.016–0.021 (1.6) 614 14.7 (14–15.4) 41 18 (14.2–22.8) <0.001
0.022–0.164 (2.3) 2245 14.3 (14–14.7) 143 18.3 (16.1–20.8) <0.001
0.165–283.0 (6.5) 2202 10.8 (10.5–11.1) 174 13.7 (12–15.8) <0.001
>283.0 (12.7) 525 7.5 (7.1–7.9) 44 7.6 (6.2–9.2) 0.941
First category ‘0.015’ represents detection limit and is the reference category. FeNO presented as
geometric mean (95%CI). Categories represent percentiles 10, 50, and 90. *Cigarettes smoked per
day represented by geometric mean (in brackets). The p value reports the statistical significant
difference between Controls and Asthma in each cotinine stratum. Numbers shown in brackets
represent the geometric mean of the self-reported average number of cigarettes per day in each
cotinine stratum. Please note the different cotinine strata in children and adults.
B-Eos count has not previously been studied in the
same subjects.
There are multiple mechanisms proposed to
explain the effect of cigarette smoke exposure on
FeNO. It has been evidenced by a series of studies that
NO in orally exhaled air primarily originates in the
respiratory epithelium, produced by inducible NO
synthase (iNOS) [4]. The basal expression of iNOS in
the human respiratory epithelium has been suggested
to be regulated by interferon gamma (IFN-γ), which is
present in normal airways [24, 25]. Further, several
studies have shown lower levels of IFN-γ and IFN-γ-
expressing cells in the airways of smokers than in those
of non-smokers [15, 26, 27]. The effect of smoking on
the formation of IFN-γ in the airways may be medi-
ated by acrolein and similar vapour phase compounds
acting on T-cells [26]. Another possible mechanism is
the reduction of L-arginine bioavailability in the
mucosa through the upregulation of epithelial argi-
nase-1 [28]. However, this seems to lead to L-arginine
deficiency in asthmatics only (with higher substrate
demand) and not in controls [29], which could explain
the finding that the effect on FeNO of increasing coti-
nine levels was slightly larger in asthmatics than in
controls. Further, oxidative processes in the airway
mucosa induced by cigarette smoke exposure may
lead to the direct consumption or scavenging of NO
[30]. Finally, exhaled NO also originates in the
pharyngo-oral tract via non-enzymatic formation
from nitrite [4], but this pathway does not seem to be
affected by smoking [31].
The association of the increase in B-Eos in healthy
controls with increasing ongoing cigarette smoke
exposure confirms previous observations [31–34].
Taylor et al [33] also reported increased levels of serum
total IgE in smokers, a phenomenon that has been
shown by others [35]. The increase of serum IgE in
smokers, although not available in the present dataset,
has been shown to be similar to that in atopic indivi-
duals [36]. However, the B-Eos count was not sig-
nificantly affected by cigarette smoke exposure in
asthmatic subjects. The mechanism behind the
increased B-Eos count in controls may involve epithe-
lial damage and the expression of alarmins, for exam-
ple thymic stromal lymphopoietin (TSLP), which have
the potential to augment type-2 inflammation [37]
and IgE formation. In asthma, TSLP is already upregu-
lated [38] and, therefore, cigarette smoke exposure
may add little to TSLP expression, explaining the lack
of effect on B-Eos count in asthmatics.
A reduction in FeNO and an increase in B-Eos
count was also seen in controls following second-hand
smoke exposure in this study, whereas FeNO was not
reduced in asthmatics following second-hand expo-
sure (there was even a trend toward an increase). This
is highly relevant given the current knowledge of the
Table 4.Effect of increasing serum cotinine on B-Eos in the control and asthma groups.
Controls Asthma
Cot. (ng ml−1) * n B-Eos n B-Eos p
All individuals
0.015 2453 122 (119–126) 157 212 (185–242) <0.001
0.016–0.021 867 128 (122–135) 62 226 (181–282) <0.001
0.022–0.122 2935 122 (118–125) 235 208 (185–234) <0.001
0.123–239.6 2903 134 (131–138) 282 213 (192–236) <0.001
>239.6 711 141 (134–149) 64 212 (178–252) <0.001
Age<18 years
0.015 677 125 (118–132) 65 268 (215–334) <0.001
0.016–0.020 206 128 (116–141) 15 302 (197–464) <0.001
0.021–0.078 740 127 (121–134) 90 253 (207–308) <0.001
0.079–2.315 701 136 (129–143) 115 259 (217–310) <0.001
>2.315 183 137 (122–153) 21 214 (165–278) 0.007
Age 18 years
0.015 1776 121 (117–126) 92 179 (152–210) <0.001
0.016–0.021 (1.6) 614 129 (122–137) 41 197 (148–262) <0.001
0.022–0.164 (2.3) 2245 120 (116–124) 143 181 (157–209) <0.001
0.165–283.0 (6.5) 2202 136 (132–140) 174 188 (167–213) <0.001
>283.0 (12.7) 525 133 (124–142) 44 225 (187–270) <0.001
First category ‘0.015’ represents detection limit and is the reference category. FeNOpresented
as geometric mean (95% CI). Categories represent percentiles 10, 50, and 90. * Cigarettes
smoked per day represented by geometric mean (in brackets). The p value reports the statistical
significant difference between Controls and Asthma in each cotinine stratum. Numbers shown
in brackets represent the geometric mean of the self-reported average number of cigarettes per
day in each cotinine stratum. Please note the different cotinine strata in children and adults.
negative effect of second-hand exposure to cigarette
smoke, with the most relevant being the depressive
effect on IFN-γ, but no change, or even an increase, in
type-2 cytokines and serum IgE [39, 40].
FeNO has previously been reported to return to
expected levels within a fewweeks after smoking cessa-
tion [41, 42]. However, only a few subjects reported
having quit smoking within the past few weeks in the
NHANES material, making it difficult to study the the
time course of the normalization of FeNO. Our results
showed no significant difference in FeNO between
former and never smokers, with the analysis under-
taken only in subjects not presently exposed to cigar-
ette smoke (undetectable serum cotinine) for the first
time. In contrast, this does not seem to be the case for
blood eosinophils, which showed persistently elevated
levels in former smokers without asthma. Similarly,
the sputum eosinophil count was shown not to
change, whereas FeNOwas normalized, after smoking
cessation in young asthmatics [42]. This effect may be
mediated by persistent TSLP formation in the airways
of former smokers [43].
Recent smoke exposure has previously been sug-
gested to be related to further reduced FeNO [22].
However, cigarette smoking has been shown to cause
both an acute reduction [44] and an increase [45] in
FeNO, and the relation between recent cigarette
smoking (within 1 h) and reduced FeNO disappeared
after correcting for serum cotinine levels in our mat-
erial. Since cotinine has a half-life of 15–20 h in blood
[18], this indicates that recent smoke exposure is a
proxy for daily cigarette smoke consumption, whereas
the actual acute effect of cigarette smoke exposure is
small and variable.
The interpretation of the results of this study
should take into consideration its strengths and
Figure 3.Effect of cotinine on FeNOandB-Eos of non-smoking controls and asthma. FeNO andB-Eos are represented by geometric
mean and 95% confidence intervals (filled squares and circle withwhiskers, respectively).#: Significant difference from the reference
cotinine stratum (0.015) at p< 0.001 (corrected for age). Categories: 1 ‘0.015’, 2 ‘0.016–0.020’, 3 3 ‘0.021–0.053’, 4 ‘0.054–9.34’, 5
‘>9.34’.
limitations. The study has a large population-based
sample, retrieved from datasets of an ongoing, well-
known and standardized national survey, with highly
controlled standard operating procedures and data
quality controls. Both FeNO and B-Eos values were
from standardized, valid and reproducible measure-
ments. In spite of the difficulty of an accurate determi-
nation of cigarette smoke exposure [13, 46], the
majority of studies have used self-reported measures
for smoking status and second-hand exposure. In this
study, we have used serum cotinine, an objective mar-
ker that increases the reliability of the analysis, in part-
icular for the detection of passive exposure in never
and former smokers. However, the assessment of
exposure to cigarette smoke using cotinine, although
more adequatelymeasured in blood than in, for exam-
ple, saliva [14], may have some inherent flaws that
could hamper the interpretation—inter-subject var-
iance in nicotine metabolism, time of day of sample
collection, and lack of adjustment of cigarette nicotine
content [47]. The classification of respiratory diseases
and the use of inhaled and oral medication was based
on self-reported data, but efforts were made to utilize
the best possible combination of questions for the
definition of asthma [48].
To conclude, in a large population-based sample of
healthy individuals and individuals with self-reported
asthma, we showed a negative association of objectively
determined exposure to cigarette smoke with exhaled
nitric oxide levels and a positive association with blood
eosinophil counts. Similar associations were also seen
for second-hand smoke exposure. These effects should
be taken into consideration in the development of nor-
malized values for these biomarkers [20, 22] and in their
interpretation in clinical practice. Furthermore, active
cigarette smoking seems to elicit type-2 inflammation
that persists after smoking cessation. The persistence of
elevated blood eosinophils in former smokers should be
studied prospectively in order to understand the risk of
future inflammatory disease.
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